Last reviewed · How we verify
intravenous hydromorphone and dexmedetomidine
Intravenous hydromorphone and dexmedetomidine, marketed by Jun Wang, holds a position in the pain management and sedation market. The key composition patent expires in 2028, providing a competitive advantage through exclusivity. The primary risk is the lack of disclosed revenue and key trial results, which may affect market confidence and investment.
At a glance
| Generic name | intravenous hydromorphone and dexmedetomidine |
|---|---|
| Also known as | HDI |
| Sponsor | Jun Wang |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- the Effect of Different Drugs and Infusion Ways on Degree of Postoperative Comfort (PHASE4)
- The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass (PHASE2)
- Studies of Application of Combined General Anesthesia and Bilateral TPVB in OPCABG (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intravenous hydromorphone and dexmedetomidine CI brief — competitive landscape report
- intravenous hydromorphone and dexmedetomidine updates RSS · CI watch RSS
- Jun Wang portfolio CI